Clinical Study of Antibodies to Shiga Toxins 1 and 2

Conditions: Prevention of Shiga toxin-mediated complications resulting from Shiga toxin producing bacterial infections.
MedDRA version: 14.1Level: LLTClassification code 10019515Term: Hemolytic uremic syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disorders
Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]

Registration Number: EUCTR2011-006094-26-Outside-EU/EEA

Lead Sponsor: Thallion Pharmaceuticals Inc

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: A

Sex: All

Target Recruitment: 42

Inclusion Criteria

1. Written, signed and dated informed consent by a parent or legally acceptable representative and age appropriate patient assent
2. Age between 6 months and 18 years (inclusively)
3. Bloody diarrhea (by visual inspection) for no more than 36 hours prior to screening.
4. Females of child-bearing potential and sexually active must have negative urine pregnancy test prior to administration of study medication. Abstain from sexual activity or use of acceptable contraceptive measures.
5. Detection of Shiga toxin (Stx1 and/or Stx2) in stool by a rapid diagnostic test (Meridian Premier EHEC Assay) or antigens from Shiga toxin producing E Coli 0157 by the ImmunoCard STAT E coli 0157 Plus test
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Laboratory findings compatible with development of at least two out of the three following criteria that define HUS: hemolytic anemia, thrombocytopenia and nephropathy
2. Bloody-diarrhea suspected not to be caused by STPB but by other organisms or preexisting diseases
3. History of renal disease or malformation. Active renal disease including infection, and isolated macrohematuria
4. Family history of proven or suspected hereditary HUS or TTP
5. Clinically significant and/or uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophtalmologic, immunologic or other significant disease
6. History of chronic/recurrent hemolytic anemia or thrombocytopenia
7. Ongoing treatment for malignancy
8. History of chronic inflammatory bowel disease
9. Prior treatment with murine, chimeric, or humanized antibody
10. Breastfeeding women